Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study

Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study

Abstract Background Tocilizumab is an IgG1 class recombinant humanized monoclonal antibody that directly inhibits the IL-6 receptor. Several randomized clinical trials have evaluated its safety and efficacy in patients with coronavirus disease 2019 (COVID-19), and these studies demonstrate conflicti...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Ohoud Aljuhani, Khalid Al Sulaiman, Adel Alshabasy, Khalid Eljaaly, Abdulrahman I. Al Shaya, Haytham Noureldeen, Mohammed Aboudeif, Bodoor Al Dosari, Amina Alkhalaf, Ghazwa B. Korayem, Muneera M. Aleissa, Hisham A. Badreldin, Shmeylan Al Harbi, Abdullah Alhammad, Ramesh Vishwakarma
Format: article
Langue:EN
Publié: BMC 2021
Sujets:
COVID-19
SARS-Cov-2
Tocilizumab
Secondary infection
CRE
Critically ill
Infectious and parasitic diseases
RC109-216
Accès en ligne:https://doaj.org/article/c8d00252251f49ceb5ec2537a6f9c97e
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
Soyez le premier à ajouter un commentaire!
Il faut se connecter d'abord

Documents similaires